BillionToOne

BillionToOne has pioneered a groundbreaking DNA molecular counter, enhancing the resolution of cell-free DNA diagnostics by more than 1,000 times. This advancement facilitates significant improvements in both prenatal screening and liquid biopsy applications for cancer detection. Their commercially available non-invasive prenatal test (NIPT), Unity Screen, stands out as the only NIPT capable of evaluating fetal risk for both recessive conditions and aneuploidies using only maternal blood. Unity Screen is experiencing rapid growth and is poised to become the new standard of care, supported by a growing body of research demonstrating its accuracy and advantages over existing screening methodologies. Furthermore, BillionToOne has leveraged its molecular counting technology to create innovative liquid biopsy tests, presenting the potential to revolutionize oncology care.